Ocugen, Inc. reports 54 percent decline in atrophic lesion growth in OCU410ST early results

Ocugen, Inc. reports 54 percent decline in atrophic lesion growth in OCU410ST early results
Ocugen 54 percent lesion cut

Ocugen, Inc. has published early results for its OCU410ST clinical trial, revealing a 54 percent reduction in the growth of atrophic lesions among treated patients.

According to the company, 100 percent of treated eyes either stabilized or improved, with participants reporting an average gain of six letters in visual acuity. These initial findings highlight the strong potential of OCU410ST in addressing atrophic eye conditions. An insight from a clinical trial participant is available through the company’s provided resources.

Ocugen is developing OCU410ST as part of its efforts to address inherited retinal diseases lacking approved therapies. The company previously reported early-stage gene therapy progress for approximately 100,000 patients with Stargardt disease who have no FDA-approved treatment options. Ocugen has also launched a modifier gene therapy platform targeting advanced retinal diseases at several industry conferences focused on solutions for inherited blindness.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.